The Proclaim XR is a result of advances in neuromodulation research and technology, said Antony, an assistant professor in the UF College of Medicine’s anesthesiology department. Delivering smaller electrical pulses gives high-quality pain relief to patients while also allowing the devices to last for years without recharging.
The Proclaim XR also is more transparent for patients: New technology means they no longer feel a tingling sensation as the device works to block pain signals. Because the device is so efficient — it provides the lowest effective dose of pain-reducing electrical pulses — patients are no longer tethered to a recharging system every day or once every few days while the battery replenishes.
“The goal is to decrease pain and, more importantly, allow patients to do things that they enjoy or haven’t been able to do before. The fact that Felix won’t have to spend time maintaining a device allows him to accomplish his goal of being more active,” Antony said.
On Oct. 2, Favicchio’s neuromodulator was activated for the first time. Using an Apple iPad mini and a proprietary app, Abbott representative Dallas Graham customized the settings to begin delivering pain relief.
“Tell me when you start to feel some relief,“ she told Favicchio.
“The pain, it’s going away,“ he said, excitedly. “This is what I
Using the iPad, Graham adjusted the amplitude, or intensity, of the neurostimulation. As the pain he had known for decades began ebbing, a smile crossed his face.
“It’s like putting water on a fire,”
Although neurostimulation isn’t new, Antony said patients are now reaping the benefits of recent technological advances in neuromodulation pain relief. Rechargeable devices debuted about 20 years ago, but they typically need to be powered up every one to two days. Abbott’s system lets doctors choose the lowest effective dose of stimulation for a patient. Using lower doses of energy in shorter cycles enables the Proclaim XR’s long battery life.
While the device might not completely end a patient’s pain, Antony said it provides a meaningful reduction that will unquestionably help Favicchio and other patients with chronic pain. Since Favicchio’s implant, eight to 10 other patients have gotten the devices implanted through late October.